Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

2.

Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.

Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS.

Clin Pharmacol Ther. 2016 Sep;100(3):287-94. doi: 10.1002/cpt.401. Epub 2016 Jun 20.

PMID:
27213804
3.

Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome.

Rossington JA, Brown OI, Hoye A.

Open Heart. 2016 Feb 26;3(1):e000296. doi: 10.1136/openhrt-2015-000296. eCollection 2016.

4.

The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy.

Polo Friz H, Molteni M, Cimminiello C.

Thromb J. 2015 Sep 7;13:28. doi: 10.1186/s12959-015-0059-8. eCollection 2015.

5.

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Yang Y, Lewis JP, Hulot JS, Scott SA.

Expert Opin Drug Metab Toxicol. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Epub 2015 Jul 14. Review.

6.
7.

Building the Case for Clopidogrel as a World Health Organization Essential Medicine.

Patel A, Vidula M, Kishore SP, Vedanthan R, Huffman MD.

Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):447-51. doi: 10.1161/CIRCOUTCOMES.115.001866. Epub 2015 Jun 2. Review. No abstract available.

8.

Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis.

Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet JP, Jacq L, Bernasconi F, Montalescot G; ACTION Study Group.

BMJ. 2014 Oct 24;349:g6269. doi: 10.1136/bmj.g6269. Review.

9.

Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Cohen MV, Downey JM.

Br J Pharmacol. 2015 Apr;172(8):1913-32. doi: 10.1111/bph.12903. Epub 2014 Nov 24. Review.

10.

Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons.

Hong KS.

J Clin Neurol. 2014 Jul;10(3):189-96. doi: 10.3988/jcn.2014.10.3.189. Epub 2014 Jul 3. Review.

11.

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY.

J Am Heart Assoc. 2014 Apr 14;3(2):e000849. doi: 10.1161/JAHA.114.000849.

12.

High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

Garabedian T, Alam S.

Cardiovasc Diagn Ther. 2013 Mar;3(1):23-37. doi: 10.3978/j.issn.2223-3652.2013.02.06. Review.

13.

Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction.

Hong MK.

Scientifica (Cairo). 2012;2012:683683. doi: 10.6064/2012/683683. Epub 2012 Sep 16. Review.

14.

The role of the interventional cardiologist in selecting antiplatelet agents in acute coronary syndromes: a 10-question strategy.

Schiele F, Meneveau N.

Eur Heart J Acute Cardiovasc Care. 2012 Jun;1(2):170-6. doi: 10.1177/2048872612450576.

15.

Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations.

Weintraub WS, Mandel L, Weiss SA.

Pharmacoeconomics. 2013 Nov;31(11):959-70. Review.

16.

P2Y12 platelet receptors: importance in percutaneous coronary intervention.

Falcão FJ, Carvalho L, Chan M, Alves CM, Carvalho AC, Caixeta AM.

Arq Bras Cardiol. 2013 Sep;101(3):277-82. doi: 10.5935/abc.20130162. Epub 2013 Aug 6. English, Portuguese.

17.

Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.

Vavalle JP, Clare R, Chiswell K, Rao SV, Petersen JL, Kleiman NS, Mahaffey KW, Wang TY.

JACC Cardiovasc Interv. 2013 Jul;6(7):709-17. doi: 10.1016/j.jcin.2013.03.010.

18.

Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes.

Kumbhani DJ, Wells BJ, Lincoff AM, Jain A, Arrigain S, Yu C, Goormastic M, Ellis SG, Blackstone E, Kattan MW.

Am J Cardiovasc Dis. 2013;3(1):39-52. Epub 2013 Feb 17.

19.

Towards personalized medicine based on platelet function testing for stent thrombosis patients.

Godschalk TC, Hackeng CM, Ten Berg JM.

Thrombosis. 2012;2012:617098. doi: 10.1155/2012/617098. Epub 2012 Dec 25.

20.

Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent.

Sinha N.

Indian Heart J. 2012 Sep-Oct;64(5):497-502. doi: 10.1016/j.ihj.2012.09.002. Epub 2012 Sep 7. Review.

Items per page

Supplemental Content

Write to the Help Desk